16th International Symposium on Viral Hepatitis and Liver Disease Global Hepatitis Summit
Toronto, Canada, June 14-17, 2018
Congress registration will open October 2017.
Abstract Submission Guidelines
Abstract Submission Open: October 2017
Abstract Submission Close: February 12, 2018
Late-Breaking Abstract Submission Opens: March 1, 2018
Late-Breaking Abstract Submission Closes: March 30, 2018
Oral Communications
Authors are invited to submit abstracts, classified by topics. Submitted abstracts will be reviewed by the Local Organising Committee and chosen for oral presentations of 10-15 minutes.
Posters
Authors are invited to present their new research findings or important ongoing research as posters related to one of the given abstract topics on the next panel.
Abstract Submission
Abstracts must be submitted via the website:
http://www.globalhepatitissummit2018.com/abstracts
The Congress secretariat is not able to accept abstracts submitted via email or fax.
When submitting your abstract please follow the instructions listed on the website and take into account the following:
- Abstracts may be submitted for Oral or Poster Presentations.
- Abstract text should be a maximum of 2,500 characters or approximately 350 words (the word count does not include the title, the author, the affiliation and up to 1 table/figure).
- Abstracts must be submitted in English.
- The first letters of major words in the title should be capitalized.
- 1 diagram, table or figure will be accepted as part of your abstract.
- The use of standard abbrevations is required. Examples include kg, g, mg, ml, L (liter), meq, m(meter), mmol/L should be expanded at first mention with the abbreviation in parentheses. Then the abbreviation used throughout the rest of the submission. Use numerals to indicate numbers, except when beginning sentences.
- Non-proprietary (generic) names should be used the first time a drug is mentioned and typed in lowercase letters; trade names are always capitalized, for example, aspirin (Bufferin).
- All abstracts and proposals must be submitted in blinded format. Identifiers such as city, province, or institution name should not be included within title or body of abstract or proposal.
- The presenting author is required to ensure that all coauthors are aware of the content of the abstract before submission to the Secretariat.
- Presenting authors of abstracts must be registered participants.
- Authors with multiple abstracts should list their names the same way on all.
- Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
- All notifications regarding the abstract status (including notification regarding acceptance) and scheduling will be sent to the presenting author(s).
Abstract Topics
Basic Science
a) Viral Hepatitis
I. Hepatitis B
II. Hepatitis C
III. Other Hepatitis Viruses
b) Animal and Tissue Culture Models
c) Fibrogenesis and Inflammation
Clinical
a) Viral Hepatitis
I. Hepatitis B
1. Treatment
2. Pathogenesis & Natural History
II. Hepatitis C
1. Treatment
2. Pathogenesis & Natural History
III. Other Hepatitis Viruses
b) NAFLD, Fibrosis
c) Other
Public Health
a) Diagnostics & Epidemiology
I. Hepatitis B
II. Hepatitis C
b) Outreach and Linkage to Care
c) Prevention and Vaccines
Contact Info
Congress Secretariat:
MCI Group Canada,
18 Keewatin Avenue, Toronto, Ontario, M4P 1Z8
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Tel: +1 416 621 2727
Registration
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Sponsorship and Exhibition
Meighan Jury
Senior Manager, Strategic Partnerships
This e-mail address is being protected from spambots. You need JavaScript enabled to view it l +1 604 661 4967
Accomodation
This e-mail address is being protected from spambots. You need JavaScript enabled to view it